Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Pfizer, Novo Nordisk Locked in High-Stakes Fight Over Obesity Drug Innovator Metsera

Pfizer and Novo Nordisk are in a heated battle to acquire obesity drug developer Metsera, driving legal and market tension.

International Business Times

Ozempic maker struggles as it loses ground to rivals in weight-loss market

Novo Nordisk cuts sales and profit forecasts as it continues to lose ground to Mounjaro firm Eli Lilly

The Guardian - UK

Big Short's Michael Burry Places $1B Put Orders Against Nvidia and Palantir in Q3, Warns of AI Bubble

Michael Burry's Scion Asset Management bets against Nvidia and Palantir, raising concerns of an AI market bubble despite their strong performance.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Covid jab presents less harm for patients than the virus itself, study reveals

It comes amid previous concerns about potential harm from the jab

The Independent UK

COVID jabs cut the risk of heart complications in kids

Vaccination has been associated with a smaller risk of rare heart conditions compared to COVID-19 infection in children, the largest study of its kind suggests.

AAP

Covid-19 jab causes fewer problems than the virus itself in youngsters – study

The new study was led by experts at UCL and the universities of Cambridge and Edinburgh.

The Independent UK

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It

Pfizer Inc's (NYSE:PFE) lawsuit. Novo Nordisk A/S' (NYSE:NVO) counterbid. And in the middle of it all — a quiet $45 million position that might turn into Andreas Halvorsen's next masterstroke. After years of fighting from the sidelines of the Ozempic boom, Pfizer is finally throwing punches.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb

Adding more drama to Metsera Inc.’s (NASDAQ:MTSR) acquisition deal, Novo Nordisk A/S (NYSE:NVO) increased the deal proposal to $62.20 per share in cash, up from $56.50.

Benzinga

Dow Dips Over 400 Points; Pfizer Earnings Top Estimates

U.S. stocks traded lower this morning, with the Dow Jones index falling more than 400 points on Tuesday.

Benzinga

Pfizer COVID-19 vaccine sales drop 25% after confusing government guidance on the shot

Previously, fall is when Americans would typically receive their vaccines

The Independent UK

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

On Tuesday, Pfizer Inc. (NYSE:PFE) reported third-quarter 2025 adjusted earnings of 87 cents, compared to $1.06 a year ago, beating the consensus of 63 cents.

Benzinga

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle

On Friday, Pfizer Inc. (NYSE:PFE) filed a lawsuit against Metsera, Inc. (NASDAQ:MTSR), its Board of Directors, and Novo Nordisk (NYSE:NVO) in a Delaware Court.

Benzinga

How To Earn $500 A Month From Pfizer Stock Ahead Of Q3 Earnings

Pfizer Inc. (NYSE:PFE) will release earnings results for the third quarter before the opening bell on Tuesday, Nov. 4.

Benzinga

Pfizer Sues Rivals Metsera, Novo Nordisk Over Alleged Interference in Merger Talks

Pfizer sues Metsera and Novo Nordisk to block a rival bid in a high-stakes obesity drug merger.

International Business Times

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Pfizer sues to stop rival bid for drugmaker Metsera by Denmark's Novo Nordisk

Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera

Benzinga

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain

Healthcare ETFs are quietly feasting on the gains from Wall Street’s latest obsession – the $150 billion obesity-drug boom. As Eli Lilly And Co (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), and Pfizer Inc (NYSE:PFE) jostle for dominance in the fast-growing GLP-1 market, investors pile into ETFs that offer diversified and far…

Benzinga

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

The Guardian - UK

Novo Nordisk bids $9bn for obesity drug maker Metsera in challenge to Pfizer

US biotech viewed as lucrative target partly because of its promising pipeline of weight-loss drugs

Get all your
news in one place.

100’s of premium titles.
One news app.

Barchart

Pfizer Stock: Is Wall Street Bullish or Bearish?

Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Euronews

AI video circulates showing Western leaders making shock revelations

The video was produced by RT and provides a disclaimer about its true nature towards the end.

International Business Times UK

MAGA-Connected Firms Hit Record Profits as Businesses Seek White House Access

Lobbying firms with ties to Donald Trump's MAGA movement are reaping record profits as corporations race to secure influence in Washington, signalling a lucrative new era for political lobbying under Trump 2.0.

Roll Call

Trump’s approach to lowering drug costs is raising questions - Roll Call

Several drug pricing experts say without key details, it’s hard to call the individual pharma deals a win for the Trump administration.

The Independent UK

COVID-19 vaccines may help some cancer patients fight tumors

The most widely used COVID-19 vaccines may offer a surprise benefit for some cancer patients by boosting their immune systems to help fight tumors

International Business Times UK

Steve Cohen's Point72 Buys $20M of Surging Biotech Stock That Recently Priced $125M Offering to Advance Myeloma Treatment

Cohen's Point72 purchased over 8 million shares of C4 Therapeutics within weeks of the company announcing phase 1 trial data of a drug to treat myeloma and raised $125 million to fund upcoming trials.

Benzinga

Mark Cuban Isn't Convinced TrumpRx Is Going To 'Change The Game' But He's Giving Them 'Credit For Trying'

Billionaire entrepreneur Mark Cuban offered rare praise for the Trump administration's push to lower prescription drug costs, calling its TrumpRx initiative “a good start,” while still acknowledging its limitations.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.